These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21990066

  • 1. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
    Karasu GT, Yesilipek MA, Karauzum SB, Uygun V, Manguoglu E, Kupesiz A, Hazar V.
    Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066
    [Abstract] [Full Text] [Related]

  • 2. [Role of chimerism monitoring and donor lymphocyte infusion in eliminating the risk of graft rejection following HSCT in thalassemia patients-review].
    Li ZF, Sun X.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1356-60. PubMed ID: 24156465
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.
    Transplantation; 2009 Dec 15; 88(11):1312-8. PubMed ID: 19996931
    [Abstract] [Full Text] [Related]

  • 4. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients.
    Chen H, Li XY, Zhan LP, Fang JP, Huang K, Li Y, Weng WJ, Xu LH, Xu HG, Zhou DH.
    Pediatr Transplant; 2020 Dec 15; 24(8):e13876. PubMed ID: 33098346
    [Abstract] [Full Text] [Related]

  • 5. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M.
    Bone Marrow Transplant; 2005 Mar 15; 35(6):601-8. PubMed ID: 15756285
    [Abstract] [Full Text] [Related]

  • 6. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
    Lisini D, Zecca M, Giorgiani G, Montagna D, Cristantielli R, Labirio M, Grignani P, Previderè C, Di Cesare-Merlone A, Amendola G, Bergami E, Mastronuzzi A, Maccario R, Locatelli F.
    Haematologica; 2008 Dec 15; 93(12):1859-67. PubMed ID: 18945748
    [Abstract] [Full Text] [Related]

  • 7. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS.
    Biol Blood Marrow Transplant; 2004 Mar 15; 10(3):171-7. PubMed ID: 14993882
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
    Caldemeyer LE, Akard LP, Edwards JR, Tandra A, Wagenknecht DR, Dugan MJ.
    Biol Blood Marrow Transplant; 2017 Nov 15; 23(11):1989-1997. PubMed ID: 28712934
    [Abstract] [Full Text] [Related]

  • 10. Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.
    Ozyurek E, Cowan MJ, Koerper MA, Baxter-Lowe LA, Dvorak CC, Horn BN.
    Bone Marrow Transplant; 2008 Jul 15; 42(2):83-91. PubMed ID: 18391990
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 17. The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia.
    Choeyprasert W, Pakakasama S, Anurathapan U, Songdej D, Sirachainun N, Sirireung S, Panthangkool W, Hongeng S.
    Pediatr Transplant; 2012 Sep 15; 16(6):E238-40. PubMed ID: 21895905
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Quantitative analysis of donor chimerism in adoptive immunotherapy following allogeneic hematopoietic stem cell transplantation].
    Tang XW, Wu DP, Sun AN, Zhu ZL, Chang WR, Ruan CG.
    Zhonghua Nei Ke Za Zhi; 2006 May 15; 45(5):359-62. PubMed ID: 16780733
    [Abstract] [Full Text] [Related]

  • 20. Clinical relevance of serial quantitative analysis of hematopoietic chimerism after allogeneic stem cell transplantation in children for severe aplastic anemia.
    Hoelle W, Beck JF, Dueckers G, Kreyenberg H, Lang P, Gruhn B, Führer M, Niethammer D, Klingebiel T, Bader P.
    Bone Marrow Transplant; 2004 Jan 15; 33(2):219-23. PubMed ID: 14647253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.